These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 27709352

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P.
    Clin Chim Acta; 2015 Feb 02; 440():16-22. PubMed ID: 25444743
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
    Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A, Crinò L.
    Ann Oncol; 2008 May 02; 19(5):883-90. PubMed ID: 18187484
    [Abstract] [Full Text] [Related]

  • 7. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
    Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP.
    Clin Breast Cancer; 2004 Jun 02; 5(2):105-16. PubMed ID: 15245613
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.
    Breast Cancer; 2015 May 02; 22(3):292-9. PubMed ID: 23749689
    [Abstract] [Full Text] [Related]

  • 9. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M.
    J Clin Oncol; 2009 Nov 20; 27(33):5552-8. PubMed ID: 19858400
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.
    Zhou J, Peng Z, Liu Y, Gong J, Zhang X, Lu M, Gao J, Li Y, Li Y, Shen L.
    J Gastroenterol; 2015 Sep 20; 50(9):955-61. PubMed ID: 25702260
    [Abstract] [Full Text] [Related]

  • 12. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
    Duchnowska R, Jassem J, Goswami CP, Dundar M, Gökmen-Polar Y, Li L, Woditschka S, Biernat W, Sosińska-Mielcarek K, Czartoryska-Arłukowicz B, Radecka B, Tomasevic Z, Stępniak P, Wojdan K, Sledge GW, Steeg PS, Badve S.
    J Neurooncol; 2015 Mar 20; 122(1):205-16. PubMed ID: 25559688
    [Abstract] [Full Text] [Related]

  • 13. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
    Tsai HP, Chen SC, Chien HT, Jan YY, Chao TC, Chen MF, Hsieh LL.
    World J Surg Oncol; 2012 Feb 17; 10():42. PubMed ID: 22339939
    [Abstract] [Full Text] [Related]

  • 14. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
    Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, Leyland-Jones B.
    J Clin Oncol; 2009 Apr 01; 27(10):1685-93. PubMed ID: 19255335
    [Abstract] [Full Text] [Related]

  • 15. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y, Peng Z, Zhang X, Gong J, Shen L.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov 25; 20(11):1293-1299. PubMed ID: 29178102
    [Abstract] [Full Text] [Related]

  • 16. Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?
    Badzek S, Kelovic VL, Plestina S, Humar I, Veir Z, Mihaljevic Z.
    Wien Klin Wochenschr; 2011 Dec 25; 123(23-24):726-31. PubMed ID: 22113445
    [Abstract] [Full Text] [Related]

  • 17. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.
    Shi HZ, Wang YN, Huang XH, Zhang KC, Xi HQ, Cui JX, Liu GX, Liang WT, Wei B, Chen L.
    World J Gastroenterol; 2017 Mar 14; 23(10):1836-1842. PubMed ID: 28348489
    [Abstract] [Full Text] [Related]

  • 18. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.
    Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C.
    Ann Oncol; 2005 Feb 14; 16(2):234-9. PubMed ID: 15668276
    [Abstract] [Full Text] [Related]

  • 19. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
    Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, Li L, Jia W, Zhang Y, Liu W, Wei W, Xie X.
    J Cancer Res Clin Oncol; 2012 Feb 14; 138(2):275-84. PubMed ID: 22116318
    [Abstract] [Full Text] [Related]

  • 20. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.
    BMC Cancer; 2015 Mar 18; 15():138. PubMed ID: 25880075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.